| Isentress (raltegravir) / Merck (MSD) |
| Completed | 1 | 22 | US | Raltegravir, Atazanavir, Reyataz, Atazanavir + Raltegravir | Bristol-Myers Squibb, Merck Sharp & Dohme LLC | HIV Infections | 12/07 | 12/07 | | |
| Completed | 1 | 18 | Europe | Raltegravir then lopinavir/ritonavir, Lopinavir/ritonavir then raltegravir | St Stephens Aids Trust | HIV Infections | 08/08 | 08/08 | | |
| Completed | 1 | 26 | Europe | Raltegravir and ezetimibe, Ezetimibe and raltegravir | St Stephens Aids Trust | HIV | 08/08 | 08/08 | | |
| Completed | 1 | 24 | Europe | Pravastatin, Selektine, Raltegravir, Isentress, Pravastatin and raltegravir, Selektine and Isentress | Radboud University Medical Center, Merck Sharp & Dohme LLC | HIV Infections | 09/08 | 10/08 | | |
| Completed | 1 | 24 | Europe | lamotrigine, Lamictal, Raltegravir | Radboud University Medical Center, Merck Sharp & Dohme LLC | HIV Infection | 10/08 | 10/08 | | |
NCT00765271: Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects |
|
|
| Completed | 1 | 29 | Europe | Abacavir, Ziagen®, Trizivir®, Kivexa®., Darunavir/ritonavir, Raltegravir | St Stephens Aids Trust | HIV | 10/08 | 10/08 | | |
NCT00746499: Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women. |
|
|
| Completed | 1 | 7 | US | Raltegravir, Isentress | University of North Carolina, Chapel Hill | Pharmacokinetics | 11/08 | 11/08 | | |
NCT00660972: Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF) |
|
|
| Completed | 1 | 40 | US | Raltegravir, RAL, Emtricitabine/tenofovir disoproxil fumarate, FTC/TDF | National Institute of Allergy and Infectious Diseases (NIAID), Adult AIDS Clinical Trials Group | HIV Infections | 01/09 | 04/10 | | |
NCT01000818: A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) |
|
|
| Completed | 1 | 18 | US | MK0518 (Raltegravir), Raltegravir, famotidine, omeprazole | Merck Sharp & Dohme LLC | HIV-1 Infection, HIV Infections | 03/09 | 03/09 | | |
NCT00982553: The Raltegravir and Ribavirin Pharmacokinetics (PK) Study |
|
|
| Completed | 1 | 14 | Europe | Ribavirin, Copegus, Raltegravir | Imperial College London | HIV Infections | 11/09 | 12/09 | | |
NCT01047995: Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects |
|
|
| Completed | 1 | 26 | Europe | Raltegravir plus Darunavir/ritonavir, darunavir = TMC114, ritonavir = Norvir trade name, raltegravir = MK-0518, brand name Isentress | St Stephens Aids Trust | HIV Infections | 12/09 | 12/09 | | |
NCT00944307: Effect of Antacids on the Pharmacokinetics of Raltegravir |
|
|
| Completed | 1 | 17 | US | raltegravir, Isentress, antacid, Isentress, Maalox Plus Extra Strength | University of Colorado, Denver | HIV Infections | 12/09 | 12/09 | | |
NCT01027182: Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers |
|
|
| Completed | 1 | 6 | RoW | Raltegravir, ISENTRESS, 400mg | Changi General Hospital, National University Hospital, Singapore, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 03/10 | 03/10 | | |
NCT01101893: A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects |
|
|
| Completed | 1 | 15 | US | Raltegravir, GSK2248761, GSK2248761 + Raltegravir | ViiV Healthcare | Infection, Human Immunodeficiency Virus | 06/10 | 06/10 | | |
GINGER, NCT01246804: The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR |
|
|
| Completed | 1 | 18 | Europe | raltegravir single dose, Isentress, ginkgo biloba multiple dose, Tavonin | Radboud University Medical Center, Merck Sharp & Dohme LLC | HIV Infections, Depression, Mild Cognitive Impairment | 03/11 | 05/11 | | |
NCT01288755: TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir |
|
|
| Completed | 1 | 24 | Europe | TMC278, Raltegravir | Tibotec Pharmaceuticals, Ireland, Raltegravir is provided by Merck. | HIV Infections | | 05/11 | | |
LIVERAL, NCT01289951: Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis |
|
|
| Completed | 1 | 10 | Europe | Raltegravir 400 mg/12hours | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus, Hepatitis C | 06/11 | 10/11 | | |
OPAL, NCT01288417: Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir |
|
|
| Completed | 1 | 24 | Europe | boceprevir, raltegravir, Isentress | Radboud University Medical Center, Merck Sharp & Dohme LLC | HIV Infections, HCV Infections | 11/11 | 12/11 | | |
REAL, NCT00667433: Raltegravir as Early Therapy in African-Americans Living With HIV Study |
|
|
| Completed | 1 | 38 | US | Raltegravir + Truvada, MK-0518; Isentress, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg | David A Wohl, MD, Merck Sharp & Dohme LLC | HIV Infections | 12/11 | 12/11 | | |
NCT01622673: A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) |
|
|
| Completed | 1 | 27 | US | Raltegravir, RAL, ISENTRESS™, MK-0518, TUMS® Ultra Strength, TUMS, calcium carbonate antacid, MINTOX® Maximum Strength, MINTOX, magnesium/aluminum hydroxide antacid | Merck Sharp & Dohme LLC | HIV Infections | 10/12 | 10/12 | | |
| Completed | 1 | 18 | Europe | Raltegravir, Rifampicin | Helen Reynolds, Liverpool University Hospitals NHS Foundation Trust | HIV, Tuberculosis | 06/13 | 07/13 | | |
| Completed | 1 | 24 | Europe | raltegravir, raltegravir dosing for 7 days, Atorvastatin | Radboud University Medical Center, Merck Sharp & Dohme LLC | HIV, Hypercholesterolaemia | 07/13 | 08/13 | | |
NCT01841593: A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers |
|
|
| Completed | 1 | 19 | Europe | Raltegravir, Isentress, Amlodipine, Amlodipine 5mg tablets | St Stephens Aids Trust | HIV | 09/13 | 09/13 | | |
NCT01930045: A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) |
|
|
| Completed | 1 | 18 | NA | Raltegravir (ISENTRESS™), MAALOX (MAL), MAALOX® MS | Merck Sharp & Dohme LLC | HIV Infections | 12/13 | 12/13 | | |
RECITAL, NCT01978782: Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (). |
|
|
| Completed | 1 | 24 | Europe | raltegravir, isentress, citalopram | Radboud University Medical Center | HIV, Depression | 04/14 | 04/14 | | |
NCT02489487: Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 |
|
|
| Completed | 1 | 24 | RoW | VM-1500, Darunavir, Ritonavir, Raltegravir | Viriom | HIV-infection | 10/14 | 10/14 | | |
NCT02473367: The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824) |
|
|
| Completed | 1 | 20 | NA | Raltegravir 1200 mg, TUMS, Leader Antacid | Merck Sharp & Dohme LLC | HIV Infection | 08/15 | 10/15 | | |
NCT01784302: The Effect of Antacids and Multivitamins on Raltegravir |
|
|
| Completed | 1 | 15 | Europe | Multivitamins, Sodium bicarbonate, Maalox Plus extra, Raltegravir 400 mg | Helen Reynolds | HIV | 02/16 | 02/16 | | |
2016-003248-34: A PHASE I TRIAL TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF RALTEGRAVIR |
|
|
| | 1 | 84 | RoW, US | Isentress, MK-0518, Granules for oral suspension, Isentress | NIAID and NICHD, Merck & Co., Inc. | New born babies at risk of acquiring HIV from their infected mothers., Babies at risk of acquiring HIV from their mothers., Diseases [C] - Virus Diseases [C02] | | | | |
NCT01780831: Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection |
|
|
| Completed | 1 | 52 | US, RoW | Raltegravir, ISENTRESS | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/17 | 04/18 | | |
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR |
|
|
| Recruiting | 1 | 10 | US | 18F-Raltegravir | University of California, San Francisco, Merck Sharp & Dohme LLC | HIV-1-infection | 11/24 | 01/25 | | |
